All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Olga Gavrilina, National Research Center for Hematology, Moscow, RU. We asked, How does COVID-19 affect outcomes in AML?
How does COVID-19 affect outcomes in AML?
In this video, Gavrilina evaluates treatment outcomes, risk factors, prognosis, and mortality rates related to patients with AML and SARS-CoV-2 infection in a real-world setting.
Use of ruxolitinib in patients with severe COVID-19
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor that has a good safety profile and is currently approved for the treatment of myelofibrosis, polycythemia vera, and acute graft-versus-host...
What is the real-world experience of R/R AML treatment with venetoclax + HMAs?
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory...
Subscribe to get the best content related to AML delivered to your inbox